Phase II Study of Ipilimumab Plus Temozolomide in Patients With Metastatic Melanoma.
Phase of Trial: Phase II
Latest Information Update: 01 Oct 2017
At a glance
- Drugs Ipilimumab; Temozolomide
- Indications Malignant melanoma
- Focus Registrational; Therapeutic Use
- 16 Aug 2016 Status changed from active, no longer recruiting to completed.
- 05 Aug 2015 Planned primary completion date changed from 1 May 2016 to 1 May 2017 as reported by ClinicalTrials.gov
- 04 Aug 2014 Planned primary completion date changed from 1 May 2015 to 1 May 2016 as reported by ClinicalTrials.gov.